Mangorx initiates efficacy studies on its patented respiratory illness prevention technology

Dallas, texas, july 24, 2024 (globe newswire) -- mangoceuticals, inc. (nasdaq: mgrx) (“ mangorx ” or the “company”), a leader in men's health and wellness products including erectile dysfunction (ed), hair growth, weight loss, and hormone replacement therapies, is excited to announce the initiation of efficacy studies on its patented respiratory illness prevention technology in collaboration with vipragen biosciences and intramont technologies, inc. notably, these trials have been pre-funded, ensuring that the company does not need to raise any additional capital for the completion of these studies, which are anticipated to be concluded in the earlier part of the 3rd quarter.
MGRX Ratings Summary
MGRX Quant Ranking